Abstract Library

#4665 Prognostic value of systemic inflammatory parameters in neuroendocrine tumour patients treated with peptide receptor radionuclide therapy – Preliminary results

Introduction: PRRT (177Lu-Dotatate) is a therapeutic option for advanced NETs (neuroendocrine tumours). Systemic inflammatory parameters, such as NLR, PLR, SII, and other ratios derived from complete blood counts, are considered prognostic markers in NETs and other malignancies.

Conference:

Presenting Author: Maciejewski A

Authors: Maciejewski A, Komarnicki P, Musiałkiewicz J, Gut P, Ruchała M,

Keywords: neuroendocrine tumour, PRRT, systemic inflammatory parameter, PLR, prognostic biomarker,

#4646 Dysregulated miRNA in patients with GEP-NEN and potential role as circulating biomarker

Introduction: Neuroendocrine neoplasms (NENs) are a class of rare and molecularly extremely heterogeneous tumours. NENs arise predominantly in the gastrointestinal (GEP) and pulmonary tracts but can also involve thyroid and breast. NENs often present with non-specific symptoms and lack early specific biomarkers, leading to frequent metastatic diagnoses and primary site challenges.

Conference:

Presenting Author:

Authors: Di Mauro A, Clemente O, Cannella L, Della Vittoria G, Neri G,

Keywords: neuroendocrine tumour, miRNome profiling, biomarker, gep-net, molecular biology,

#4602 The role of microbiome diversity in neuroendocrine tumour (NET) development and progression: Insights from a cohort study

Introduction: The gut microbiome may influence neuroendocrine tumour (NET) development, particularly gastrointestinal NETs, yet data on this connection within Pakistan are limited. This study explores microbiome diversity’s role in NET progression.

Conference:

Presenting Author: Fatima A

Authors: Fatima A,

Keywords: Bacterial imbalance, Prognostic biomarker,

#4549 Alpha-Fetoprotein as a valuable biomarker in neuroendocrine tumours

Introduction: Neuroendocrine tumours (NETs) are a rare group of tumours that pose a significant diagnostic, therapeutic, and prognostic challenge. This complexity arises from the diversity and heterogeneity of these neoplasms, as well as from the limitations of commonly used biomarkers in clinical practice. Alpha-fetoprotein (AFP) is a fetal protein widely used primarily for congenital defects in prenatal diagnostics and in certain malignancies in adults.

Conference:

Presenting Author:

Authors: Musiałkiewicz J, Gut P, Komarnicki P, Maciejewski A, Ruchała M,

Keywords: alpha-fetoprotein, biomarker, neuroendocrine tumour,

#4521 [18F]FDG (FDG) PET/CT metrics as prognostic biomarkers in the AGITG NABNEC trial

Introduction: NABNEC was a prospective phase II trial investigating carboplatin/nab-paclitaxel in patients with advanced Grade 3 NENs (NCT02215447).

Conference:

Presenting Author: Kong G

Authors: Kong G, Ayati N, Brown C, Siu D, Mak W,

Keywords: Prognostic marker, prospective trial, chemotherapy, PET imaging, FDG, metabolic tumour volume, suv,